First order of business....
Press Release Source: Abraxis BioScience, Inc.
Marty J. Duvall Joins Abraxis BioScience as Senior Vice President, Global Marketing and International Commercial Operations
On Friday May 22, 2009, 8:05 am EDT
Buzz up! Print Related:Abraxis BioScience, Inc.
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ: ABII - News), a fully integrated biotechnology company, today announced that Marty J. Duvall has joined the management team as Senior Vice President, Global Marketing and International Commercial Operations.
Related Quotes
Symbol Price Change
ABII 47.44 0.00
{"s" : "abii","k" : "c10,l10,p20,t10","o" : "","j" : ""} “Marty has a successful track record of building brands and significantly contributing to the growth of companies in the oncology arena,” said Lonnie Moulder, President and CEO of Abraxis BioScience. “He and his team will be responsible for expanding the ABRAXANE brand franchise, both geographically and by launching new indications. We are very pleased to have this experienced executive join our growing team as we advance our mission to enhance the lives of cancer patients throughout the world.”
Mr. Duvall most recently served as Chief Business Officer, Morphotek, a subsidiary of Eisai Corporation of North America, following Eisai’s acquisition of MGI PHARMA, INC., where he served as Sr. Vice President, Commercial Operations (2004-2006) and Sr. Vice President, Commercial Strategy and Development (2007-2008). Previously, Mr. Duvall served for nearly 19 years in a number of commercial roles at Sanofi-Aventis and its predecessor companies. During that tenure, his responsibilities included Vice President, Global Medical and Marketing, with a focus on Taxotere®, and Vice President, Marketing for the U.S. Oncology Business Unit. He earned a bachelor of science degree in chemistry from Muhlenberg College, a master degree in chemistry from The Johns Hopkins University, and a master of business administration degree from the University of Kansas. |
